David T Broome, MD

 David Tyler Broome MD.jpg
Clinical Assistant Professor of Internal Medicine, Medical School
Office:
University of Michigan
24 Frank Lloyd Wright Dr., Lobby C, Suite 1300
Ann Arbor, Michigan 48105
Available to mentor
David T Broome, MD
David Tyler Broome MD.jpg
Clinical Assistant Professor
  • About
  • Qualifications
  • Center Memberships
  • Recent Publications

  • Manage Your Profile

    • About

    David T. Broome, MD, MS, is a Clinical Assistant Professor of Medicine at the University of Michigan. Dr. Broome's research is in type 1 diabetes (T1D) screening & prevention, conducting clinical trials for novel therapeutics in diabetes, and Maturity Onset Diabetes of the Young (MODY). He currently is an investigator for several NIH/NIDDK and industry sponsored clinical trials dedicated to T1D screening & prevention, and MODY-Monogenic Diabetes [including TrialNet, the Rare and Atypical Diabetes Network (RADIANT), βETA PRESERVE, and An Observational, Long-Term Safety Study of TZIELD (teplizumab-mzwv) in Patients with Stage 2 Type 1 Diabetes, PRECIDENTD], and Co-Chairs the PREcision DIabetes ConsorTium (PREDICT; which is the largest multi-center MODY data collaboration agreement in the United States). He was the recipient of several teaching & research awards and currently serves as a Co-Chair on the Publications Committee for the T1D Exchange, Review Editor for Frontiers in Clinical Diabetes and Healthcare, and serves on the editorial board for the Journal of Clinical Endocrinology & Metabolism (JCEM). In his free time, Dr. Broome enjoys ice hockey, cycling, and spending time with family and friends on the beach in Holland, MI.

    Qualifications
    • Endocrinology Fellow
      Cleveland Clinic Foundation, United States
      2019 - 2021
      Clinical Fellowship
    • Internal Medicine Resident
      Cleveland Clinic Foundation, Cleveland, United States
      2016 - 2019
      Residency
    • MS, Health and Healthcare Research
      University of Michigan, Ann Arbor, United States
      2025 - 2026
    • MD
      Wayne State University, Detroit, Michigan, United States
      2012 - 2016

    Center Memberships
    • Center Member
      AI and Digital Health Innovation
    • Center Member
      Institute for Healthcare Policy and Innovation
    • Center Member
      Caswell Diabetes Institute

    Recent Publications

     See All Publications
    • Journal Article
      A Real-World Beta-Cell Preservation Framework in Type 1 Diabetes: Consensus from the T1D Exchange (T1DX-QI).
      Demeterco-Berggren C, Broome DT, Alonso GT, Sherr JL, DeSalvo DJ, Simmons K, Culbreth L, Rapp AK, Gelick B, Lonier J, Fogel NR, Levin L, McCauley M, Tuttle AR, Raman V, Choudhary A, Ilkowitz J, Gallagher MP, Majidi S, Holly SL, Rainey C, Rioles N, Wright T, Jacobsen LM. Endocr Pract, 2026 Oct 16; DOI:10.1016/j.eprac.2026.10.003
      PMID: 42887691
    • Journal Article
      A Novel Electronic Medical Record Search Method to Identify Patients With Ketosis-Prone Diabetes: Implications for Discovery of Atypical Diabetes.
      Ahmed M, Kubota-Mishra E, Siller AF, Davis A, Migacz I, Sisley S, Faruqi JA, Saeed ZI, Ahmed S, Philipson L, Redondo MJ, Balasubramanyam A, Tosur M, RADIANT Study Group* . Diabetes Care, 2026 Sep 1; 49 (9): 1608 - 1612. DOI:10.2337/dc26-0464
      PMID: PMC13493332
    • Proceeding / Abstract / Poster
      Identifying Lipodystrophy in Atypical Diabetes Using a High-Specificity Clinical Prediction Model: Insights from the RADIANT Study.
      Pyreddy A, Yang Y, Guler M, Besci O, Maloney K, Gomes A, Aly Y, Sisley S, Broome D, Krischer J, Philipson L, Pollin T, Balasubramanyam A, Oral E. Journal of the Endocrine Society, 2026 Jun 14;
    • Proceeding / Abstract / Poster
      Integrative Genomics Reveals Molecular Drivers of Lipodystrophy in the RADIANT Study.
      Guler M, Foss-Freitas M, Hashimoto H, Pyreddy A, Besci O, Maloney K, Dill Gomes A, Aly Y, Yang Y, Sisley S, Broome D, Krischer J, Philipson L, Pollin T, Balasubramanyam A, Chun T-H, Yamamoto S, Stone S, Oral E. Journal of the Endocrine Society, 2026 Jun 14;
    • Proceeding / Abstract / Poster
      SUN-548 Dual GIP/GLP-1 Receptor Agonist Use in PDX1-MODY: A Case Report.
      Gillespie L, Reinert R, Chase C, Gelick B, Thomas I, Oral E, Philipson L, Broome D. Journal of the Endocrine Society, 2026 Jun 14;
    • Proceeding / Abstract / Poster
      SUN-549 GLP-1 RA and Dual GIP/GLP-1 RA in HNF1A-MODY and HNF4A-MODY: An Observational, Cross-Sectional Analysis of the PREcision DIabetes ConsorTium (PREDICT).
      Broome D, Douvas J, Shams A, Deng L, Gelick B, Gillespie L, Chase C, McCullough M, Tosur M, Kreienkamp R, Naylor R, Greeley S, Krishnamurthy M, Oral E, Pollin T, Rasouli N, Udler M, Philipson L. Journal of the Endocrine Society, 2026 Jun 14;
    • Presentation
      Endocrinology Fellows Presentation: Diabetes Complications: Diabetic Neuropathy.
      Broome D. 2026 Jun 2;
    • Journal Article
      Advancing Monogenic Diabetes Research and Clinical Care by Creating a Data Commons: The Precision Diabetes Consortium (PREDICT)
      McCullough ME, Letourneau-Freiberg LR, Naylor RN, Greeley SAW, Broome DT, Tosur M, Kreienkamp RJ, Cobry E, Rasouli N, Pollin TI, Udler MS, Billings LK, Desouza C, Evans-Molina C, Birz S, Furner B, Watkins M, Ott K, Volchenboum SL, Philipson LH. Journal of Diabetes Science and Technology, 2026 May 1; 20 (3): 1034 - 1040. DOI:10.1177/19322968241310896
      PMID: 39781649

    Featured News & Stories

         football player in middle of parents on field smiling
    Health Lab

    Using genetic testing, doctors help patient find answers for her diabetes

    For 30 years Autumn Caris thought she had type 1 diabetes. After learning about MODY, a rare and often misdiagnosed type of diabetes, she finally got answers at U-M.
         2025 Dean's Lecture and Bold Science Symposium
    Medical School News

    2025 Dean’s Lecturer: GLP-1 therapies saving, improving lives of many patients

    Lives are being saved, and many others are being changed dramatically, by current GLP-1 therapies like tirzepatide, which has helped many patients treat type 2 diabetes and sleep apnea, and also lose weight. It has been a long road from bench research to clinical trials to the health care market, but patients are now benefitting more than ever, according to a leading scientist who served as the keynote speaker for the second annual Dean’s Lecture and Bold Science Symposium, “Metabolism Research from Bench to Bedside.” Daniel Skovronsky, M.D., Ph.D., chief scientific officer and executive vice president of science and technology at Eli Lilly and Company and president of Research Laboratories and Lilly Immunology, was the Dean’s Lecturer on April 14 at the North Campus Research Complex Dining Hall.